751 related articles for article (PubMed ID: 16286363)
21. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
22. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
23. Low molecular weight heparins for venous thromboembolism.
Drug Ther Bull; 1998 Apr; 36(4):25-9. PubMed ID: 9684414
[TBL] [Abstract][Full Text] [Related]
24. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
[TBL] [Abstract][Full Text] [Related]
25. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Cheer SM; Dunn CJ; Foster R
Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
[TBL] [Abstract][Full Text] [Related]
26. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
28. Treatment of DVT: how long is enough and how do you predict recurrence.
Agnelli G; Becattini C
J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
[TBL] [Abstract][Full Text] [Related]
29. Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weight heparin for recurrent venous thrombosis.
Thachil J
Ann Pharmacother; 2014 Mar; 48(3):420-4. PubMed ID: 24473488
[TBL] [Abstract][Full Text] [Related]
30. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
[TBL] [Abstract][Full Text] [Related]
31. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Rahme E; Feugère G; Sirois C; Weicker S; Ramos E
Thromb Res; 2013 Mar; 131(3):210-7. PubMed ID: 23290095
[TBL] [Abstract][Full Text] [Related]
33. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
Martineau P; Tawil N
Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
[TBL] [Abstract][Full Text] [Related]
34. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
Dranitsaris G; Vincent M; Crowther M
Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
[TBL] [Abstract][Full Text] [Related]
35. Emerging options in the treatment of venous thromboembolism.
Nutescu EA
Am J Health Syst Pharm; 2004 Dec; 61(23 Suppl 7):S12-7. PubMed ID: 15597574
[TBL] [Abstract][Full Text] [Related]
36. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Schiff RL; Kahn SR; Shrier I; Strulovitch C; Hammouda W; Cohen E; Zukor D
Chest; 2005 Nov; 128(5):3364-71. PubMed ID: 16304285
[TBL] [Abstract][Full Text] [Related]
37. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists.
Kher A; Samama MM
J Thromb Haemost; 2005 Mar; 3(3):473-81. PubMed ID: 15748236
[TBL] [Abstract][Full Text] [Related]
38. [Evolution in the pharmacological treatment of venous thrombosis according to evidence-based medicine].
Manganaro A; Giannino D; Lembo D; Bruni F; Consolo F
Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):41-51. PubMed ID: 11253339
[TBL] [Abstract][Full Text] [Related]
39. Selecting an agent for prophylaxis of venous thromboembolism.
Myers J
Am J Health Syst Pharm; 2006 Dec; 63(24):2448-50. PubMed ID: 17158692
[No Abstract] [Full Text] [Related]
40. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.
Simonneau G; Laporte S; Mismetti P; Derlon A; Samii K; Samama CM; Bergman JF;
J Thromb Haemost; 2006 Aug; 4(8):1693-700. PubMed ID: 16796710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
